Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about CSF_p-tau217: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| NRGN | correlated_trajectory_with | protein | 0.00 |
| amyloid_PET | normalizes_faster_than | imaging_biomarker | 0.00 |
| ds-a0bfdf291ec1 | provides_data_for | dataset | 1.00 |
| Source | Relation | Type | Str |
|---|---|---|---|
| amyloid_plaques | drives_elevation_via | pathological_structure | 0.00 |
| CAA | prevents_complete_normalization_of | pathological_condition | 0.00 |
| axonal_transport | weakly_related_to | biological_process | 0.00 |
| CST3 | affects_clearance_of | protein | 0.00 |
| ds-a0bfdf291ec1 | data_in | dataset | 1.00 |
| AQP4 | affects_clearance_of | channel_protein | 0.55 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Temporal Decoupling of CSF p-tau217 Normalization from Amylo | 0.595 | neurodegeneration | - |
| CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Patho | 0.586 | neurodegeneration | - |
| Residual Vascular Amyloid Prevents Complete CSF p-tau217 Nor | 0.560 | - | Can CSF p-tau217 normalization serve as |
| CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET N | 0.540 | - | Can CSF p-tau217 normalization serve as |
| CSF p-tau217 Normalization Requires Intact Synaptic Function | 0.515 | neurodegeneration | - |
| CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clini | 0.512 | neurodegeneration | - |
| Amyloid Plaque Clearance Triggers Downstream Reduction in Ta | 0.450 | - | Can CSF p-tau217 normalization serve as |
| Axonal Integrity Recovery Following Amyloid Clearance Drives | 0.340 | - | Can CSF p-tau217 normalization serve as |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.560
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning CSF_p-tau217 in their description or question text
Score: 0.450 · unknown disease · 2026-04-26
Donanemab-mediated amyloid plaque clearance reduces microglial activation and neuronal injury, which diminishes the path
Score: 0.340 · unknown disease · 2026-04-26
Donanemab treatment reduces amyloid-induced axonal transport deficits and endosomal trafficking impairment. Restored axo